Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hisoar Pharma Invests RMB 150 Million in Wanbangde’s WP205 for ALS, Securing 15 % Global Revenue Share

Fineline Cube Jan 13, 2026
Company Deals

Bayer AG Acquires Cardiac Amyloidosis Imaging Tracers from Attralus, Including Phase III AT‑01 with FDA Breakthrough Designation

Fineline Cube Jan 13, 2026
Company Deals

RemeGen Licenses RC148 Bispecific to AbbVie for Up to $5.6 Billion in Milestones

Fineline Cube Jan 13, 2026
Company Deals

Boehringer Ingelheim & Jazz Launch Phase I HER2 Breast Cancer Combo with Zongertinib & Zanidatamab

Fineline Cube Jan 13, 2026
Company Deals Digital

Thermo Fisher Scientific Partners with NVIDIA in $280 Million AI Deal to Automate Laboratory Operations

Fineline Cube Jan 13, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes

Fineline Cube Jan 13, 2026
Company Drug

CSPC’s Prusogliptin/Metformin FDC NDA Accepted by NMPA for Type 2 Diabetes, Targeting 60 M Underserved Patients

Fineline Cube Jan 13, 2026
Company Drug

Shanghai BDgene Technology Receives US FDA Approval for HSV-1 Stromal Keratitis Gene Therapy

Fineline Cube Jul 10, 2023

Gene therapy specialist Shanghai BDgene Technology Co., Ltd has announced receiving approval from the US...

Company Medical Device

Jenscare Scientific’s LuX-Valve Plus Accepted for US FDA Review in IDE Process

Fineline Cube Jul 10, 2023

Ningbo-based structural heart disease intervention device manufacturer, Jenscare Scientific Co., Ltd (HKG: 9877), has announced...

Company Medical Device

Broncus Medical Inc. Launches First Regulatory Clinical Study for Targeted Lung Denervation System

Fineline Cube Jul 10, 2023

China-based Broncus Medical Inc., (HKG: 2216), a provider of precision intervention solutions focused on lung...

Company Deals Digital

Hainan Boao Lecheng Partners with Medlive for Medical Tourism and Online Doctor Education

Fineline Cube Jul 10, 2023

The Hainan Boao Lecheng International Medical Tourism Pilot Zone has entered into a strategic partnership...

Company Drug

HutchMed Ltd Initiates Phase I Clinical Study for SHP2 Inhibitor HMPL-415 in Solid Tumors

Fineline Cube Jul 10, 2023

China-based HutchMed Ltd (NASDAQ: HCM; HKG: 0013) has announced the initiation of a Phase I...

Company

GenScript Biotech Expands cGMP Manufacturing for Gene and Cell Therapy in Zhenjiang Facility

Fineline Cube Jul 10, 2023

China-based GenScript Biotech Corporation (HKG: 1548) has announced the expansion of its current Good Manufacturing...

Policy / Regulatory

China’s NAFR Enhances Tax Benefits for Private Health Insurance Purchases

Fineline Cube Jul 7, 2023

The National Administration of Financial Regulation (NAFR) in China has issued a Notification indicating that...

Company Deals

Jacobio Pharma Secures RMB 150 Million Investment to Advance Pipeline Programs

Fineline Cube Jul 7, 2023

China-based Jacobio Pharma (HKG: 1167) has announced receiving RMB 150 million (USD 20.7 million) in...

Company Medical Device

Genesis MedTech Secures Chinese Market Approval for ArtiSential Laparoscopic Surgical Device

Fineline Cube Jul 7, 2023

Singapore-based Genesis MedTech has announced that it has received market approval in China for its...

Company Drug

Shanghai Fosun Pharmaceutical Submits Daxibotulinumtoxin A (RT002) for NMPA Approval

Fineline Cube Jul 7, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a China-based pharmaceutical company, has announced a...

Company Drug

Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-1703 Clinical Study

Fineline Cube Jul 7, 2023

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a China-based pharmaceutical company, has announced receiving approval...

Company Deals

C-Mer Eye Care Holdings Ltd Partners with Hong Kong Ophthalmologist for Novel Drug Development

Fineline Cube Jul 7, 2023

China-based C-Mer Eye Care Holdings Ltd (HKG: 3309) has announced the establishment of a joint...

Company Deals

ChengDu ShengNuo Biotechnology Aims to Raise RMB 160 Million for Peptide Drug CDMO Expansion

Fineline Cube Jul 7, 2023

China-based ChengDu Shengnuo Biotechnology Co., Ltd., (SHA: 688117) has announced plans to raise up to...

Company Medical Device

Peijia Medical Receives NMPA Approval for DCwire Micro Guide Wire Device in China

Fineline Cube Jul 7, 2023

Peijia Medical Ltd (HKG: 9996), a leading Chinese firm in the neurointerventional field, has announced...

Company Deals

Chime Biologics, Leads Biolabs, and BeiGene Form Strategic Partnership for LAG-3 mAb LBL-007

Fineline Cube Jul 7, 2023

Wuhan-based Contract Development and Manufacturing Organization (CDMO) Chime Biologics has signed a strategic cooperation agreement...

Company Deals

Sirnaomics Ltd Partners with Edirna Inc. to Advance RNA Editing Therapy

Fineline Cube Jul 6, 2023

Sirnaomics Ltd (HKG: 2257), a leading company in the field of RNA therapeutics, has announced...

Policy / Regulatory

CDE Launches Trial Procedures for Adding Pediatric Information to Drug Inserts

Fineline Cube Jul 6, 2023

The Center for Drug Evaluation (CDE) has released the “Work Procedures for Adding Children’s Drug...

Company Deals

Sino Biopharmaceutical’s F-star Therapeutics Inks Third Licensing Deal with Takeda for Immunotherapies

Fineline Cube Jul 6, 2023

Sino Biopharmaceutical Ltd (HKG: 1177) has announced a third licensing agreement between its subsidiary, F-star...

Company Drug

3SBio Inc. Receives NMPA Approval for Nalfurafine Tablets to Treat Hemodialysis-Related Pruritus

Fineline Cube Jul 6, 2023

China-based 3SBio Inc. (HKG: 1530) has announced receiving marketing approval from the National Medical Products...

Company Deals

Tot Biopharmaceutical and GL-Biotech Collaborate on DisacLink Technology for ADC Advancements

Fineline Cube Jul 6, 2023

China-based Tot Biopharma International Co., Ltd (HKG: 1875) has announced a strategic partnership with compatriot...

Posts pagination

1 … 448 449 450 … 609

Recent updates

  • Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes
  • CSPC’s Prusogliptin/Metformin FDC NDA Accepted by NMPA for Type 2 Diabetes, Targeting 60 M Underserved Patients
  • Lifetech’s CS Stent System Wins NMPA Fast‑Track for Aortic Arch Aneurysms, Eliminates Cerebral Ischemia Risk
  • ImmuneOnco’s Timdarpacept Receives NMPA Nod for Atherosclerosis Study, Expanding CD47 Platform
  • Hengrui’s SHR‑1826 ADC Earns Breakthrough Therapy Designation for c‑Met Overexpressed NSCLC
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Sanofi’s Teizeild Wins EU Approval as First Disease‑Modifying Therapy for Type 1 Diabetes

Company Drug

CSPC’s Prusogliptin/Metformin FDC NDA Accepted by NMPA for Type 2 Diabetes, Targeting 60 M Underserved Patients

Company Medical Device

Lifetech’s CS Stent System Wins NMPA Fast‑Track for Aortic Arch Aneurysms, Eliminates Cerebral Ischemia Risk

Company Drug

ImmuneOnco’s Timdarpacept Receives NMPA Nod for Atherosclerosis Study, Expanding CD47 Platform

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.